Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $124.18.
Several equities analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Disc Medicine from $120.00 to $127.00 and gave the company a “buy” rating in a report on Friday, November 6th. Wells Fargo & Company raised their target price on Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Cantor Fitzgerald raised their target price on Disc Medicine from $125.00 to $170.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Guggenheim began coverage on Disc Medicine in a research report on Monday, November 9th. They set a “buy” rating and a $132.00 price target for the company. Finally, Wedbush boosted their price target on Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, October 19th.
View Our Latest Stock Analysis on Disc Medicine
Insider Transactions at Disc Medicine
In other news, insider William Savage sold 16,035 shares of Disc Medicine stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the completion of the transaction, the insider directly owned 63,445 shares of the company’s stock, valued at $5,398,535.05. The trade was a 20.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 150,277 shares of company stock valued at $11,877,059 in the last 90 days. 3.76% of the stock is currently owned by company insiders.
Institutional Trading of Disc Medicine
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Legal & General Group Plc purchased a new stake in shares of Disc Medicine in the second quarter valued at approximately $1,350,000. Bank of America Corp DE acquired a new position in shares of Disc Medicine during the 2nd quarter worth approximately $9,882,000. Squarepoint Ops LLC lifted its position in shares of Disc Medicine by 139.3% during the 2nd quarter. Squarepoint Ops LLC now owns 75,872 shares of the company’s stock valued at $5,549,000 after buying an additional 44,163 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock valued at $62,535,000 after buying an additional 434,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock valued at $73,280,000 after buying an additional 735,300 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.
Disc Medicine Trading Down 4.3%
NASDAQ IRON opened at $76.59 on Tuesday. The company has a market capitalization of $3.49 billion, a PE ratio of -12.08 and a beta of 0.96. The company has a fifty day moving average of $71.54 and a 200 day moving average of $71.05. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 24.14.
Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10. Research analysts forecast that Disc Medicine will post -6.20 earnings per share for the current year.
About Disc Medicine
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.
Featured Stories
- Five stocks we like better than Disc Medicine
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
